Metsera's FY2025 EPS Forecast Adjusted Downward by Cantor Fitzgerald

On March 27, 2025, Cantor Fitzgerald analysts announced a revision to their earnings per share (EPS) forecast for Metsera, Inc. (NASDAQ:MTSR). According to the research note released to investors, analyst P. Agrawal has lowered the expected EPS for the fiscal year 2025 to ($3.58), a decrease from the previous estimate of ($3.38). Despite this adjustment, Cantor Fitzgerald maintains an "Overweight" rating on Metsera's stock, indicating a positive outlook compared to other stocks.

Recently, Metsera released its earnings results on March 26, 2025, reporting an EPS of ($3.52) for the quarter. This result aligns closely with the downward adjustment made by Cantor Fitzgerald.

Additionally, other equity analysts have shared their insights on Metsera. On February 25, 2025, Evercore ISI initiated coverage with an "outperform" rating. Bank of America also started coverage on the same day, assigning a "buy" rating along with a price target of $38.00. Furthermore, Guggenheim issued a "buy" rating and set a price objective of $56.00 for Metsera.

Market Performance

As of Monday, Metsera’s stock opened at $27.22. The stock has experienced fluctuations, with a fifty-two week range stretching from a low of $23.08 to a high of $32.81.

About Metsera, Inc.

Metsera, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation injectable and oral nutrient-stimulated hormone analog peptides, also known as NuSH, aimed at treating obesity, overweight, and related health conditions. The company’s product pipeline includes MET-097i, MET-233, and MET-224o.

Future Observations

Investors are advised to keep an eye on Metsera's upcoming developments and market performance, especially in light of the adjusted EPS forecasts. Further analysis and market movements will offer greater context for future investments.

forecast, EPS, Metsera